Macrophage PD-L1 Loss Reduces CD80 Surface Expression

Researchers at Mayo Clinic and the University of Utah have identified a specific intrinsic role for PD-L1 in macrophages, finding that the loss of this protein reduces the surface expression of CD80. Published in Frontiers in Oncology, this original research article utilizes complementary genetic and pharmacological approaches to clarify how PD-L1 expression impacts the immunomodulatory phenotype of macrophages.

The central research question addresses a gap in understanding the tumor microenvironment, where macrophages are known to upregulate PD-L1 expression to suppress T cells through PD-1 ligation. While the role of PD-L1 in inhibiting T cell activity is well established, the manner in which PD-L1 expression intrinsically affects the macrophages themselves has remained less clear. By investigating this knowledge gap, the team aimed to provide further insight into macrophage function and its regulatory mechanisms within the complex landscape of tumor biology.

To characterize the macrophage intrinsic role of PD-L1, the investigators employed a dual-method strategy involving both genetic and pharmacological interventions. The study analyzed primary murine bone marrow-derived macrophages with complete genetic PD-L1 deletion alongside wildtype macrophages treated with anti-PD-L1 blocking antibodies.

The experimental design involved evaluating macrophages across three distinct polarization states: naïve, pro-inflammatory, and tumor conditioned.

Contrary to prior reports, the study found that neither genetic deletion nor antibody blockade dramatically altered the expression of standard macrophage polarization markers. Furthermore, the in vitro phagocytic capacity of the macrophages remained largely unaffected by the loss of PD-L1.

However, both genetic deletion and antibody blockade consistently and robustly reduced surface levels of CD80, a key costimulatory molecule.

The observed reduction in CD80 levels prompted further analysis of other T cell interacting and antigen presentation associated surface proteins. The researchers revealed disparate effects of expression in response to PD-L1 genetic deletion versus antibody blockade.

Collectively, these findings suggest that the loss of macrophage PD-L1 reduces CD80 expression and regulates immunoregulatory surface protein expression in vitro.

The research was conducted by a collaborative team including Trinity Waddell, Haidong Dong, Minna Roh-Johnson, and Jessica Naomi Lancaster from Mayo Clinic Arizona, Mayo Clinic Minnesota, and the University of Utah. The article, received in June 2026 and accepted in October 2026, contributes to the growing body of literature on cancer molecular targets and therapeutics.

Subject of Research: Intrinsic role of PD-L1 in macrophage CD80 expression and immunoregulatory phenotype

Article Title: PD-L1 deletion or blockade intrinsically reduces macrophage CD80 levels

Article References: Waddell, T., Dong, H., Roh-Johnson, M., & Lancaster, J. N. (2026). PD-L1 deletion or blockade intrinsically reduces macrophage CD80 levels. Frontiers in Oncology, 16, Article 1917545. https://doi.org/10.3389/fonc.2026.1917545

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1917545

Keywords: PD-L1, Macrophages, CD80, Tumor Microenvironment, Immunology, Oncology, Antigen Presentation, Checkpoint Inhibitors, deletion, blockade, intrinsically, reduces